Applied Clinical Trials
Only eight percent of CNS drugs will reach approval, in part because of the high adverse effects standards.
Pierre Geoffroy
Advertisement
Articles by Pierre Geoffroy
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy
2
ACT Brief: FDA CRL Transparency Pause, Protocol-Centric Recruitment Model Shift, and Medical Affairs Integration in Development
3
ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion
4
Bringing the Voice of Clinical Practice and Patients into Drug Development
5